Buy Lenvatinib 4 mg Online, Buy Lenvima online, Buy Kisplyx online
Lenvacent 4 (Lenvima) Lenvatinib 4 mg is used to treat recurrent, metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Lenvacent is the alternative & generic version of Lenvima by Eisai. Lenvacent is manufactured by Incepta Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.
Therapeutic Class
Targeted Cancer Therapy
Pharmacology
Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 5′-triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
Dosage & Administration
Differentiated thyroid cancer (DTC): The recommended dosage is 24 mg orally once daily.
Renal cell carcinoma (RCC): The recommended dosage is 18 mg orally once daily with everolimus 5 mg orally once daily.
Hepatocellular carcinoma (HCC): The recommended dosage is based on actual body weight:
-
12 mg orally once daily for patients greater than or equal to 60 kg
-
8 mg orally once daily for patients less than 60 kg.